Completed PHASE2 INTERVENTIONAL 1-arm NCT00363051

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy

Sponsor: Novartis Pharmaceuticals

Conditions Islet Cell Carcinoma Neuroendocrine Carcinoma Neuroendocrine Tumor Pancreatic Neoplasms

Interventions Everolimus 10 mg Octreotide Depot

Updated 7 times since 2017 Last updated: May 6, 2013 Started: Jun 30, 2006 Primary completion: Jan 31, 2008 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Islet Cell Carcinoma and Neuroendocrine Carcinoma and is currently completed. Novartis Pharmaceuticals leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Barcelona, Spain , Berlin, Germany , Billancourt, France , Birmingham, United States , Boston, United States , Buenos Aires, Argentina , Clichy, France , Columbus, United States , Durham, United States and 42 more locations